0.46
+0.0549(+13.51%)
Currency In USD
| Previous Close | 0.41 |
| Open | 0.44 |
| Day High | 0.47 |
| Day Low | 0.43 |
| 52-Week High | 1.33 |
| 52-Week Low | 0.26 |
| Volume | 499,654 |
| Average Volume | 295,232 |
| Market Cap | 28.66M |
| PE | -0.45 |
| EPS | -1.02 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.53 |
| Change | 0.05 |
If you invested $1000 in Passage Bio, Inc. (PASG) since IPO date, it would be worth $20.77 as of July 07, 2025 at a share price of $0.461. Whereas If you bought $1000 worth of Passage Bio, Inc. (PASG) shares 3 years ago, it would be worth $186.72 as of July 07, 2025 at a share price of $0.461.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire Inc.
Jun 23, 2025 11:00 AM GMT
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days
Passage Bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN an